R&D technologies

Multi-stages controlled release technology
Orient Pharma has developed (1) unique technology for semi-solid/liquid formulation and (2)patentable multi-filling equipment. The technology and the equipment are applied for semi-solid/liquid filling in the same capsule. The distinguishing features of the technology are as follows：

1) Suitable for highly sensitized drugs and can reduce environment pollution.
2) Able to modulate different formulations to enhance bioavailability of the drugs.
3) Able to formulate incompatible ingredients with different physical and chemical characteristics into a
unit product.
4) Rapid release formulation and sustained release formulation can be combined into a unit product.
5) The patentable formulations can be applied in manufacturing controlled drugs to reduce the drug abuse.
6) Able to simplify the manufacturing process.

Patent application for the technology was approved in Republic of China and Japan in 2008 and 2011 subsequently. Orient Pharma is using this technology for joint research and development of a new drug with Durect Corporation. Please refer to the following website for more information：
http://business.highbeam.com/436238/article-1G1-206120604/durect-signs-development-and-license-agreement-orient

Trans-dermal patches
The unique trans-dermal patches technology is applied to improve general patches on the market, prolong the shelf life, increase patient acceptance and drug adherence, and enhance drug efficacy. International patents for the technology have been applied and the relevant information has been released to the public. Prototype of products derived from this technology has been tested in human body successfully and the discussion about cooperation and technology licensing with international pharmaceutical companies is ongoing. Please refer to the following website below for more information：
http://www.faqs.org/patents/app/20090297591

Oral disintegrating tablets
Technology for oral disintegrating tablets is (ODT) derived from that for general tablets. However, compared to general tablets, the major differences of ODT are: the disintegrating time is between 5-30 seconds, and the manufacturing standards for the physical characteristics should follow those for general tablets. Therefore, the level of formulation design and the technology is higher than it is for general tablets. Currently, the technology is successfully applied in developing several series of products. Following the aging trend nowadays, this dosage form dominates the market and is designed for travellers, the elderly, and children who have difficulty in swallowing tablets.

Sustained release technology
The major strength of sustained release technology is that the active ingredient is sustainably released and maintains stable in different gastrointestinal areas with varied pH value. Other strength is to improve patient adherence and to reduce drug related side effects. This technology is currently being well developed in the market. The sustained release technology includes framework sustained release tablets, thin film coated sustained release tablets, and dual-layer sustained release tablets. Currently, the technology is applied successfully to develop several framework sustained release tablets.

Microgranules
Microgranules include enteric-coated microgranules capsules, enteric-coated microgranules tablets, sustained release microgranules capsules, sustained release microgranules tablets, and oral integrating sustained release microgranules tablets. Currently, the technology and instruments are applied successfully in developing several sustained release microgranules tablets and capsules.

The major strength of microgranules is that the active ingredient is stably released, or maintains stable and is sustainably released in gastrointestinal areas with varied pH value. This is the core technology of Orient Pharma and is applied in manufacturing products with Orient Pharma brand equity. In the future, the technology is expected to bring more profit to Orient Pharma.